Amgen vs Iovance Biotherapeutics
Amgen (AMGN) and Iovance Biotherapeutics (IOVA) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $236B
- Last close
- $435.64
- 12 months
- +29.6%
- Market value
- $3.19B
- Last close
- $6.90
- 12 months
- +216.5%
At a glance
- The biggest part of Iovance Biotherapeutics's revenue is Amtagvi, 83% of the total in its last annual report.
- Amgen earns 72% of its revenue in the United States, Iovance Biotherapeutics 98%.
- By market value, Amgen ($235.6B) is about 74 times Iovance Biotherapeutics ($3.2B).
- Over the last 12 months Amgen's share price moved +29.6% and Iovance Biotherapeutics's +216.5%; against the S&P 500 that is +23.9 points and +210.8 points.
- In their last fiscal years Amgen kept 21.0% of revenue as net income and Iovance Biotherapeutics -148.4%.
- In the last 90 days insiders reported 0 open-market purchases at Amgen and 0 at Iovance Biotherapeutics; members of Congress disclosed 6 trades in Amgen and 0 in Iovance Biotherapeutics.
- Next results: Amgen Feb 1, 2027, Iovance Biotherapeutics Feb 22, 2027.
How each one makes money: Amgen revenue · Iovance Biotherapeutics revenue
Share prices on one chart
Amgen and Iovance Biotherapeutics, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Amgen AMGNNASDAQ · Biotechnology | Iovance Biotherapeutics IOVANASDAQ · Biological Products, (No Diagnostic Substances) | |
|---|---|---|
| Size and profitability | ||
| Market value | $236B | $3.19B |
| Revenue, last fiscal year | $36.8B | $264M |
| Net income, last fiscal year | $7.71B | −$391M |
| Net marginNet income as a share of revenue | 21.0% | -148.4% |
| Free cash flow | ||
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Amgen against
Common questions
How is Amgen different from Iovance Biotherapeutics?
Amgen (AMGN) is in Biotechnology on NASDAQ, with $36.8B of revenue in its last fiscal year and a net margin of 21.0%. Iovance Biotherapeutics (IOVA) is in Biological Products, (No Diagnostic Substances) on NASDAQ, with $264M of revenue in its last fiscal year and a net margin of -148.4%. The biggest part of Iovance Biotherapeutics's revenue is Amtagvi, 83% of the total in its last annual report. Amgen earns 72% of its revenue in the United States, Iovance Biotherapeutics 98%. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Amgen and Iovance Biotherapeutics compare in size?
Amgen has the larger market value: Amgen $236B and Iovance Biotherapeutics $3.19B, at the last close.
Whose share price rose more over the last 12 months, AMGN or IOVA?
Over the last 12 months Amgen moved +29.6% and Iovance Biotherapeutics +216.5%. Past price moves say nothing about the future.
Which has had more insider buying, Amgen or Iovance Biotherapeutics?
Since 2006, Iovance Biotherapeutics insiders reported 31 open-market purchases against 9 for Amgen. These are counts of what was filed, not a view on either stock.
Do members of Congress trade AMGN or IOVA?
In the last 12 months, members of Congress disclosed 17 trades in Amgen (AMGN) and 0 in Iovance Biotherapeutics (IOVA).
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Amgen pageIovance Biotherapeutics pageRare insider trades this weekAll comparisons
https://oqro.io/compare/amgn-vs-iova







